EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada

Jenna Shaw iD, Mahmoud Elsawy, Rachel Nielsen, Amye Michelle Harrigan, Tara T DiCostanzo, Laura V Minard iD

Current Oncology · 24.12.2024 · 32 (1) · 2

DOI: 10.3390/curroncol32010002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 24.12.2024. Verfasst von Jenna Shaw und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nova Scotia Health, QEII Health Sciences Centre, Halifax, NS B3H 2Y9, Canada. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nova Scotia (NS) began offering CAR T-cell therapy as a third-line standard of care for eligible patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) in 2022. Recipients of CAR T-cell therapy often experience acute toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which require close monitoring and prompt management. This retrospective review aimed to describe the characteristics of adult patients with r/r LBCL deemed eligible to receive CAR T-cell therapy with axicabtagene ciloleucel in NS between January 2022 and June 2024, the toxicities experienced and toxicity management, hospital visits and intensive care unit (ICU) admissions, the utilization of toxicity management guidelines, and general efficacy outcomes. Twenty-seven patients received axicabtagene ciloleucel. All patients experienced CRS (7.4% grade ≥ 3), and 55.6% developed ICANS (25.9% grade ≥ 3). The median hospital stay was 18 days, with 40.7% requiring ICU admission. There was one treatment-related mortality. Most CRS (85.2%) and ICANS (80.0%) cases were managed according to the guidelines. By day +100, the best objective response rate was 81.5% (44.4% complete responses). Patients who received CAR T-cell therapy in NS, Canada, experienced comparable toxicities and efficacy to those reported in pivotal clinical trials and other real-world experiences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseHumansFemaleNova ScotiaMaleMiddle AgedRetrospective StudiesAgedAdultCytokine Release SyndromeBiological Products

Stichwörter der Autor:innen

CAR T-cell therapyaxicabtagene ciloleucelguideline adherenceguideline utilizationlarge B-cell lymphomatoxicity management

Substanzen

axicabtagene ciloleucelBiological Products

Autor:innen und Institutionen

  • Department of Pharmacy, Nova Scotia Health, QEII Health Sciences Centre, Halifax, NS B3H 2Y9, Canada.
  • QEII Health Sciences Centre, Division of Hematology and Hematologic Oncology, Dalhousie University, Halifax, NS B3H 4R2, Canada.
  • Cell Therapy and Transplant Program, Nova Scotia Health, QEII Health Sciences Centre, Halifax, NS B3H 2Y9, Canada.

ORCID-Profile: Jenna Shaw, Laura V Minard

Zitieren

APA

Shaw, J., Elsawy, M., Nielsen, R., Harrigan, A. M., DiCostanzo, T. T., & Minard, L. V. (2024). Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada. Current Oncology, 32(1), 2. https://doi.org/10.3390/curroncol32010002

Vancouver

Shaw J, Elsawy M, Nielsen R, Harrigan AM, DiCostanzo TT, Minard LV. Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada. Current Oncology. 2024;32(1):2. doi:10.3390/curroncol32010002

BibTeX
@article{Shaw2024,
  author = {Shaw, Jenna and Elsawy, Mahmoud and Nielsen, Rachel and Harrigan, Amye Michelle and DiCostanzo, Tara T and Minard, Laura V},
  title = {Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada},
  journal = {Current Oncology},
  year = {2024},
  volume = {32},
  number = {1},
  pages = {2},
  doi = {10.3390/curroncol32010002}
}
Kostenlos starten →